Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference

-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-

-Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high number needed to harm (NNH)-

BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the virtual American Thoracic Society (ATS) 2021 International Conference.

"We are pleased to have the opportunity to showcase the significant potential of our clinical development portfolio at ATS," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "The breadth of data presented across our three programs demonstrates our significant progress as we advance through clinical development with the goal of delivering transformative therapies to patients living with diseases that have previously been overlooked and underserved."

Summaries of these presentations are as follows:

ARIKAYCE

Oral Title: "Incremental Mortality Associated with Nontuberculous Mycobacterial Lung Disease Among US Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease"

Data were presented from a retrospective cohort study that used the US Medicare claims database to assess the incremental burden of mortality associated with nontuberculous mycobacterial (NTM) lung disease in patients with underlying chronic obstructive pulmonary disease (COPD). A total of 4,926 cases (COPD patients with NTM lung disease) were matched to 14,778 controls (COPD patients without NTM lung disease). Mean follow-up was 2.6 years for cases and 3.1 years for controls. The study showed the following key findings:

• A higher proportion of patients with both COPD and NTM lung disease died during follow-up than patients with COPD without NTM lung disease (41.5% vs. 26.7%; p